Selection of a company to carry out a patented test as part of a clinical trial involving patients with locally advanced squamous cell carcinoma of the head and neck (EC... The purpose of this contract is to carry out a test patented diagnostic, developed within the Saint Luc University Clinics, as part of a clinical trial involving patients with locally advanced squamous cell carcinoma of the head and neck (CETC LA). The successful bidder must be available from May 15, 2026. Description of the clinical trial: This public procurement concerns a prospective academic phase II clinical trial in patients with locally advanced squamous cell carcinoma of the head and neck (LA-HNSCC) negative for human papillomavirus (HPV). The trial is a multi-center Belgian national study, involving 10 participating centers in Belgium, coordinated by the Cliniques universitaire Saint-Luc (CUSL), with UZ Gent acting as the coordinating center for the Flanders. Participating centers include UZ Gent, UZ Leuven, VITAZ/UZA, UZ Brussel, Institut Jules Bordet, CHU UCL Namur, Grand Hôpital de Charleroi, CHU Liège and CHU HELORA (La Louvière, Site Jolimont). The main objective of this trial is to evaluate the clinical utility of circulating tumor DNA (ctDNA) as a biomarker for •molecular stratification of basic risk; •the detection of minimal residual disease (MRD) after treatment with curative intent; •molecular monitoring longitudinal during follow-up. At baseline, all patients will undergo assessment of PD-L1 expression (combined positive score, CPS) and ctDNA status using...
-
10 Mar 2026
-
135361533
-
Refer Document